PDA Technical Report No. 79 (TR 79) Particulate Matter Control in Difficult to Inspect Parenterals (single user digital version)

Published
Mar 2018
ISBN
9781945584022
Pages
36
PDA Item Number
43536

Premium Members: to claim your annual free technical document download, email membership@pda.org and indicate the document you wish to claim.

Format
PDF Single user
Member Price
$180.00
Nonmember Price
$325.00
Government Price
$180.00

PDA Technical Report No. 79, Particulate Matter Control in Difficult to Inspect Parenterals describes best practices for difficult to inspect parenteral (DIP) product lifecycle management, destructive testing, and trending to supplement portions of the guidance given in USP General Chapter<1790>: Visible Particulates in Injection.

In 2015, the PDA Task Force on Particulate Matter Control in Difficult to Inspect Parenterals initiated an industry survey on DIP products. literature, pharmacopeial references, and the collective expertise of Task Force contributors form the basis for the information provided in this technical report.

This Technical Report is intended to provide logical pathways to DIP product inspection and testing to support continual process improvement in the industry.

Available to download. Prior to purchase please view the download instructions and Terms of Usage.
Format: PDF (1 file 1.05 MB)

Click here to order paper ship version (Item no. 01079).

*To purchase licensing, please contact PDA at info@pda.org.

Table of Contents

Table of Contents:

Click here to download >>> Detailed Table of Contents
  1. Introduction
  2. Glossary
  3. Overview
  4. Expectations for DIP Inspection
  5. Inspection Approaches for DIP Products/Containers/Devices
  6. Defect Prevention: A Lifecycle Approach
  7. Conclusion
  8. References
  9. Appendix 1: Enhanced Methods for Revealing Visible Particles

Figures and Tables Index

About the Authors

Roy Cherris, Bridge Associates International- InQuest Science, Co-Chair

Ulrich Valley, PhD, Novartis, Co-Chair

Lars Aabye-Hansen, Novo Nordisk

Roy McLean, Baxter

Dirk Overroedder, PhD, Johnson and Johnson

Amy Owen, Hospira, a Pfizer Company

John Shabushnig, PhD, Insight Pharma Consulting, LLC

Scott Aldrich, Ultramikro LLC

Romain Veillon, GSK Vaccines

Rick Watson, Merck Sharp & Dohme Corp.